Stephen Maxted Ansell, MD, PhD

  • 22862 Citations
  • 81 Scopus h-Index
1989 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Article
Article

Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era

Taparra, K., Liu, H., Polley, M. Y., Ristow, K., Habermann, T. M. & Ansell, S. M., Jan 1 2019, (Accepted/In press) In : Leukemia and Lymphoma.

Research output: Contribution to journalArticle

B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenström macroglobulinemia

Elsawa, S. F., Novak, A. J., Grote, D. M., Ziesmer, S. C., Witzig, T. E., Kyle, R. A., Dillon, S. R., Harder, B., Gross, J. A. & Ansell, S. M., Apr 1 2006, In : Blood. 107, 7, p. 2882-2888 7 p.

Research output: Contribution to journalArticle

76 Scopus citations
71 Scopus citations

Bowel perforation in intestinal lymphoma: Incidence and clinical features

Vaidya, R., Habermann, T. M., Donohue, J. H., Ristow, K. M., Maurer, M. J., Macon, W. R., Colgan, J. P., Inwards, D. J., Ansell, S. M., Porrata, L. F., Micallef, I. N., Johnston, P. B., Markovic, S. N., Thompson, C. A., Nowakowski, G. S. & Witzig Dr., T. E., Sep 1 2013, In : Annals of Oncology. 24, 9, p. 2439-2443 5 p., mdt188.

Research output: Contribution to journalArticle

49 Scopus citations

Brentuximab vedotin: Delivering an antimitotic drug to activated lymphoma cells

Ansell, S. M., Jan 1 2011, In : Expert Opinion on Investigational Drugs. 20, 1, p. 99-105 7 p.

Research output: Contribution to journalArticle

26 Scopus citations

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: A phase 1, open-label, dose-escalation study

Younes, A., Connors, J. M., Park, S. I., Fanale, M., O'Meara, M. M., Hunder, N. N., Huebner, D. & Ansell, S. M., Dec 1 2013, In : The Lancet Oncology. 14, 13, p. 1348-1356 9 p.

Research output: Contribution to journalArticle

194 Scopus citations

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

LaCasce, A. S., Gregory Bociek, R., Sawas, A., Caimi, P., Agura, E., Matous, J., Ansell, S. M., Crosswell, H. E., Islas-Ohlmayer, M., Behler, C., Cheung, E., Forero-Torres, A., Vose, J., O’Connor, O. A., Josephson, N., Wang, Y. & Advani, R., Jul 5 2018, In : Blood. 132, 1, p. 40-48 9 p.

Research output: Contribution to journalArticle

48 Scopus citations

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

Ramchandren, R., Advani, R. H., Ansell, S. M., Bartlett, N. L., Chen, R., Connors, J. M., Feldman, T., Forero-Torres, A., Friedberg, J. W., Gopal, A. K., Gordon, L. I., Kuruvilla, J., Savage, K. J., Younes, A., Engley, G., Manley, T. J., Fenton, K. & Straus, D. J., Jan 1 2019, In : Clinical Cancer Research. 25, 6, p. 1718-1726 9 p.

Research output: Contribution to journalArticle

Open Access
12 Scopus citations

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Straus, D. J., Długosz-Danecka, M., Alekseev, S., Illés, Á., Picardi, M., Lech-Maranda, E., Feldman, T., Smolewski, P., Savage, K. J., Bartlett, N. L., Walewski, J., Ramchandren, R., Zinzani, P. L., Hutchings, M., Connors, J. M., Radford, J., Munoz, J., Kim, W. S., Advani, R., Ansell, S. M. & 6 others, Younes, A., Miao, H., Liu, R., Fenton, K., Forero-Torres, A. & Gallamini, A., Mar 5 2020, In : Blood. 135, 10, p. 735-742 8 p.

Research output: Contribution to journalArticle

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma

Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., Younes, A., Alekseev, S., Illés, A., Picardi, M., Lech-Maranda, E., Oki, Y., Feldman, T., Smolewski, P., Savage, K. J., Bartlett, N. L., Walewski, J., Chen, R., Ramchandren, R., Zinzani, P. L. & 9 others, Cunningham, D., Rosta, A., Josephson, N. C., Song, E., Sachs, J., Liu, R., Jolin, H. A., Huebner, D. & Radford, J., Jan 25 2018, In : New England Journal of Medicine. 378, 4, p. 331-344 14 p.

Research output: Contribution to journalArticle

190 Scopus citations

Cause of death in follicular lymphoma in the first decade of the rituximab era: A pooled analysis of French and US cohorts

Sarkozy, C., Maurer, M. J., Link, B. K., Ghesquieres, H., Nicolas, E., Thompson, C. A., Traverse-Glehen, A., Feldman, A. L., Allmer, C., Slager, S. L., Ansell, S. M., Habermann, T. M., Bachy, E., Cerhan, J. R. & Salles, G., Jan 10 2019, In : Journal of Clinical Oncology. 37, 2, p. 144-152 9 p.

Research output: Contribution to journalArticle

23 Scopus citations
11 Scopus citations

CD4+CD25+FOXP3+ malignant T cells in Sézary syndrome are not necessarily functional regulatory T cells

Wada, D. A., Pittelkow, M. R., Comfere, N. I., Gibson, L. E., Ansell, S. M. & Wilcox, R. A., Sep 2013, In : Journal of the American Academy of Dermatology. 69, 3, p. 485-489 5 p.

Research output: Contribution to journalArticle

6 Scopus citations
117 Scopus citations

CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma

Burington, B., Yue, P., Shi, X., Advani, R., Lau, J. T., Tan, J., Stinson, S., Stinson, J., Januario, T., De Vos, S., Ansell, S., Forero-Torres, A., Fedorowicz, G., Yang, T. T. C., Elkins, K., Du, C., Mohan, S., Yu, N., Modrusan, Z., Seshagiri, S. & 9 others, Yu, S. F., Pandita, A., Koeppen, H., French, D., Polson, A. G., Offringa, R., Whiting, N., Ebens, A. & Dornan, D., Mar 16 2011, In : Science translational medicine. 3, 74, 74ra22.

Research output: Contribution to journalArticle

28 Scopus citations

CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25- T cells

Yang, Z. Z., Novak, A. J., Ziesmer, S. C., Witzig, T. E. & Ansell, S. M., Oct 1 2007, In : Blood. 110, 7, p. 2537-2544 8 p.

Research output: Contribution to journalArticle

126 Scopus citations

CDDO-imidazolide mediated inhibition of malignant cell growth in Waldenström macroglobulinemia

Elsawa, S. F., Novak, A. J., Grote, D., Konopleva, M., Andreeff, M., Witzig, T. E. & Ansell, S. M., Dec 1 2008, In : Leukemia Research. 32, 12, p. 1895-1902 8 p.

Research output: Contribution to journalArticle

5 Scopus citations
26 Scopus citations

Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma

Bennani, N., Thanarajasingam, G. & Ansell, S. M., Feb 17 2016, (Accepted/In press) In : Expert Review of Clinical Immunology. p. 1-7 7 p.

Research output: Contribution to journalArticle

2 Scopus citations

Chronological age is a multifactorial prognostic variable in patients with non-Hodgkin's lymphoma

Ansell, S. M., Falkson, G., Van Der Merwe, R. & Uys, A., Jan 1992, In : Annals of Oncology. 3, 1, p. 45-50 6 p.

Research output: Contribution to journalArticle

Open Access
25 Scopus citations

Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy

Farooq, U., Maurer, M. J., Thompson, C. A., Thanarajasingam, G., Inwards, D. J., Micallef, I., Macon, W., Syrbu, S., Lin, T., Lin, Y., Ansell, S. M., Nowakowski, G. S., Habermann, T. M., Cerhan, J. R. & Link, B. K., Oct 1 2017, In : British Journal of Haematology. 179, 1, p. 50-60 11 p.

Research output: Contribution to journalArticle

16 Scopus citations

Clinical outcome of patients with subcutaneous panniculitis-like T-cell lymphoma

Ghobrial, I. M., Weenig, R. H., Pittlekow, M. R., Qu, G., Kurtin, P. J., Ristow, K. & Ansell, S. M., May 1 2005, In : Leukemia and Lymphoma. 46, 5, p. 703-708 6 p.

Research output: Contribution to journalArticle

49 Scopus citations

Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

Jurinovic, V., Kridel, R., Staiger, A. M., Szczepanowski, M., Horn, H., Dreyling, M. H., Rosenwald, A., Ott, G., Klapper, W., Zelenetz, A. D., Barr, P. M., Friedberg, J. W., Ansell, S. M., Sehn, L. H., Connors, J. M., Gascoyne, R. D., Hiddemann, W., Unterhalt, M., Weinstock, D. M. & Weigert, O., Aug 25 2016, In : Blood. 128, 8, p. 1112-1120 9 p.

Research output: Contribution to journalArticle

73 Scopus citations
18 Scopus citations

Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells

Paulus, A., Akhtar, S., Caulfield, T., Samuel, K., Yousaf, H., Bashir, Y., Paulus, S. M., Tran, D., Hudec, R., Cogen, D., Jiang, J., Edenfield, B., Novak, A. J., Ansell, S. M., Witzig, T. E., Martin, P., Coleman, M., Roy, V., Ailawadhi, S., Chitta, K. & 2 others, Linder, S. & Chanan Khan, A. A., Nov 4 2016, In : Blood Cancer Journal. 6, 11, e492.

Research output: Contribution to journalArticle

21 Scopus citations

Comparison of error rates in single-arm versus randomized phase II cancer clinical trials

Tang, H., Foster, N. R., Grothey, A., Ansell, S. M., Goldberg, R. M. & Sargent, D. J., Apr 10 2010, In : Journal of Clinical Oncology. 28, 11, p. 1936-1941 6 p.

Research output: Contribution to journalArticle

61 Scopus citations

Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity

Elsawa, S. F., Novak, A. J., Ziesmer, S. C., Almada, L. L., Hodge, L. S., Grote, D. M., Witzig, T. E., Fernandez-Zapico, M. E. & Ansell, S. M., Nov 17 2011, In : Blood. 118, 20, p. 5540-5549 10 p.

Research output: Contribution to journalArticle

50 Scopus citations

Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenström's macroglobulinemia

Hodge, L. S., Ziesmer, S. C., Yang, Z. Z., Secreto, F. J., Novak, A. J. & Ansell, S. M., Feb 13 2014, In : Blood. 123, 7, p. 1055-1058 4 p.

Research output: Contribution to journalArticle

11 Scopus citations

Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization

Micallef, I. N. M., Sinha, S., Gastineau, D. A., Wolf, R., Inwards, D. J., Gertz, M. A., Hayman, S. R., Hogan, W. J., Johnston, P. B., Lacy, M. Q., Ansell, S. M., Buadi, F., Dingli, D., Dispenzieri, A., Litzow, M. R., Porrata, L. F., Winters, J. L. & Kumar, S., Jan 1 2013, In : Biology of Blood and Marrow Transplantation. 19, 1, p. 87-93 7 p.

Research output: Contribution to journalArticle

59 Scopus citations

CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis

Charbonneau, B., Wang, A. H., Maurer, M. J., Asmann, Y. W., Zent, C. S., Link, B. K., Ansell, S. M., Weiner, G. J., Ozsan, N., Feldman, A. L., Witzig, T. E., Cunningham, J. M., Dogan, A. M., Habermann, T. M., Slager, S. L., Novak, A. J. & Cerhan, J. R., Sep 1 2013, In : Cancer Immunology, Immunotherapy. 62, 9, p. 1475-1484 10 p.

Research output: Contribution to journalArticle

17 Scopus citations

Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts

Ghesquières, H., Maurer, M. J., Casasnovas, O., Ansell, S. M., Larrabee, B. R., Lech-Maranda, E., Novak, A. J., Borrel, A. L., Slager, S. L., Brice, P., Allmer, C., Brion, A., Ziesmer, S. C., Morschhauser, F., Habermann, T. M., Gaillard, I., Link, B. K., Stamatoullas, A., Fermé, C., Dogan, A. & 4 others, Macon, W. R., Audouin, J., Cerhan, J. R. & Salles, G., Nov 1 2013, In : Cytokine. 64, 2, p. 523-531 9 p.

Research output: Contribution to journalArticle

15 Scopus citations

Cytokines in the microenvironment of Waldenström's macroglobulinemia

Elsawa, S. & Ansell, S., Jan 1 2009, In : Clinical Lymphoma and Myeloma. 9, 1, p. 43-45 3 p.

Research output: Contribution to journalArticle

10 Scopus citations

Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: A randomized, double-blind, placebo-controlled phase 2b trial

Fayad, L., Ansell, S. M., Advani, R., Coiffier, B., Stuart, R., Bartlett, N. L., Forero-Torres, A., Kuliczkowski, K., Belada, D., Ng, E. & Drachman, J. G., Sep 2 2015, In : Leukemia and Lymphoma. 56, 9, p. 2569-2578 10 p.

Research output: Contribution to journalArticle

15 Scopus citations
26 Scopus citations

Defining lymphoplasmacytic lymphoma: Does MYD88L265P define a pathologically distinct entity among patients with an IgM paraprotein and bone marrow-based low-grade b-cell lymphomas with plasmacytic differentiation?

Fang, H., Kapoor, P., Gonsalves, W., Frederick, L. A., Viswanatha, D., Howard, M. T., He, R., Morice, W. G., McPhail, E., Greipp, P. T., Ansell, S. M., Kyle, R. A., Gertz, M., Paludo, J., Abeykoon, J. & King, R., Jul 3 2018, In : American Journal of Clinical Pathology. 150, 2, p. 168-176 9 p.

Research output: Contribution to journalArticle

2 Scopus citations

Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma

Ansell, S. M., Tang, H., Kurtin, P. J., Koenig, P. A., Nowakowski, G. S., Nikcevich, D. A., Nelson, G. D., Yang, Z., Grote, D. M., Ziesmer, S. C., Silberstein, P. T., Erlichman, C. & Witzig, T. E., May 2012, In : Leukemia. 26, 5, p. 1046-1052 7 p.

Research output: Contribution to journalArticle

13 Scopus citations

Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma

Cerhan, J. R., Fredericksen, Z. S., Wang, A. H., Habermann, T. M., Kay, N. E., Macon, W. R., Cunningham, J. M., Shanafelt, T. D., Ansell, S. M., Call, T. G., Witzig, T. E., Slager, S. L. & Liebow, M., Jun 13 2011, In : International Journal of Molecular Epidemiology and Genetics. 2, 2, p. 95-113 19 p.

Research output: Contribution to journalArticle

31 Scopus citations
2 Scopus citations

Detection of t(2;5) in anaplastic large cell lymphoma: Comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue

Cataldo, K. A., Jalal, S. M., Law, M. E., Ansell, S. M., Inwards, D. J., Fine, M., Arber, D. A., Pulford, K. A. & Strickler, J. G., Nov 1 1999, In : American Journal of Surgical Pathology. 23, 11, p. 1386-1392 7 p.

Research output: Contribution to journalArticle

96 Scopus citations

Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute- Waldenström Macroglobulinemia 1

Chitta, K. S., Paulus, A., Ailawadhi, S., Foster, B. A., Moser, M. T., Starostik, P., Masood, A., Sher, T., Miller, K. C., Iancu, D. M., Conroy, J., Nowak, N. J., Sait, S. N., Personett, D. A., Coleman, M., Furman, R. R., Martin, P., Ansell, S. M., Lee, K. & Chanan-Khan, A. A., Feb 1 2013, In : Leukemia and Lymphoma. 54, 2, p. 387-396 10 p.

Research output: Contribution to journalArticle

16 Scopus citations

Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia

Vitale, L. A., He, L. Z., Thomas, L. J., Widger, J., Weidlick, J., Crocker, A., O'Neill, T., Storey, J., Glennie, M. J., Grote, D. M., Ansell, S. M., Marsh, H. & Keler, T., Jul 15 2012, In : Clinical Cancer Research. 18, 14, p. 3812-3821 10 p.

Research output: Contribution to journalArticle

45 Scopus citations

Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia

Paludo, J., Abeykoon, J. P., Kumar, S., Shreders, A., Ailawadhi, S., Gertz, M. A., Kourelis, T., King, R. L., Reeder, C. B., Leung, N., Kyle, R. A., Buadi, F. K., Habermann, T. M., Dingli, D., Witzig, T. E., Dispenzieri, A., Lacy, M. Q., Go, R. S., Lin, Y., Gonsalves, W. I. & 5 others, Warsame, R., Lust, J. A., Rajkumar, S. V., Ansell, S. M. & Kapoor, P., Oct 2017, In : British journal of haematology. 179, 1, p. 98-105 8 p.

Research output: Contribution to journalArticle

7 Scopus citations
51 Scopus citations

Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials

Maurer, M. J., Ghesquières, H., Link, B. K., Jais, J. P., Habermann, T. M., Thompson, C. A., Haioun, C., Allmer, C., Johnston, P. B., Delarue, R., Micallef, I. N., Peyrade, F., Inwards, D. J., Ketterer, N., Farooq, U., Fitoussi, O., Macon, W. R., Molina, T. J., Syrbu, S., Feldman, A. L. & 8 others, Slager, S. L., Weiner, G. J., Ansell, S. M., Cerhan, J. R., Salles, G. A., Witzig, T. E., Tilly, H. & Nowakowski, G. S., Jun 1 2018, In : Journal of Clinical Oncology. 36, 16, p. 1603-1610 8 p.

Research output: Contribution to journalArticle

30 Scopus citations

Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: Are they two different diseases?

Ghobrial, I. M., Habermann, T. M., Macon, W. R., Ristow, K. M., Larson, T. S., Walker, R. C., Ansell, S. M., Gores, G. J., Stegall, M. D. & McGregor, C. G., Jan 27 2005, In : Transplantation. 79, 2, p. 244-247 4 p.

Research output: Contribution to journalArticle

116 Scopus citations

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

Lohr, J. G., Stojanov, P., Lawrence, M. S., Auclair, D., Chapuy, B., Sougnez, C., Cruz-Gordillo, P., Knoechel, B., Asmann, Y. W., Slager, S. L., Novak, A. J., Dogan, A. M., Ansell, S. M., Link, B. K., Zou, L., Gould, J., Saksena, G., Stransky, N., Rangel-Escareño, C., Fernandez-Lopez, J. C. & 14 others, Hidalgo-Miranda, A., Melendez-Zajgla, J., Hernández-Lemus, E., Schwarz-Cruz y Celis, A., Imaz-Rosshandler, I., Ojesina, A. I., Jung, J., Pedamallu, C. S., Lander, E. S., Habermann, T. M., Cerhan, J. R., Shipp, M. A., Getz, G. & Golub, T. R., Mar 6 2012, In : Proceedings of the National Academy of Sciences of the United States of America. 109, 10, p. 3879-3884 6 p.

Research output: Contribution to journalArticle

597 Scopus citations

Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing

Feldman, A. L., Dogan, A., Smith, D. I., Law, M. E., Ansell, S. M., Johnson, S. H., Porcher, J. C., Özsan, N., Wieben, E. D., Eckloff, B. W. & Vasmatzis, G., Jan 20 2011, In : Blood. 117, 3, p. 915-919 5 p.

Research output: Contribution to journalArticle

190 Scopus citations

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Gopal, A. K., Chen, R., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Connors, J. M., Engert, A., Larsen, E. K., Chi, X., Sievers, E. L. & Younes, A., Feb 19 2015, In : Blood. 125, 8, p. 1236-1243 8 p.

Research output: Contribution to journalArticle

137 Scopus citations

Early event status informs subsequent outcome in newly diagnosed follicular lymphoma

Maurer, M. J., Bachy, E., Ghesquières, H., Ansell, S. M., Nowakowski, G. S., Thompson, C. A., Inwards, D. J., Allmer, C., Chassagne-Clément, C., Nicolas-Virelizier, E., Sebban, C., Lebras, L., Sarkozy, C., Macon, W. R., Feldman, A. L., Syrbu, S. I., Traverse-Glehan, A., Coiffier, B., Slager, S. L., Weiner, G. J. & 5 others, Witzig, T. E., Habermann, T. M., Salles, G., Cerhan, J. R. & Link, B. K., 2016, (Accepted/In press) In : American Journal of Hematology.

Research output: Contribution to journalArticle

87 Scopus citations

Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphoma

Kelly, J. L., Drake, M. T., Fredericksen, Z. S., Asmann, Y. W., Liebow, M., Shanafelt, T. D., Feldman, A. L., Ansell, S. M., Macon, W. R., Herr, M. M., Wang, A. H., Nowakowski, G. S., Call, T. G., Habermann, T. M., Slager, S. L., Witzig, T. E. & Cerhan, J. R., Jul 1 2012, In : Cancer Causes and Control. 23, 7, p. 1017-1029 13 p.

Research output: Contribution to journalArticle

27 Scopus citations